Loading clinical trials...
Loading clinical trials...
Drug-eluting Bead Transarterial Chemoembolization Compared With Conventional Transarterial Chemoembolization as the Conversion Therapy for Unresectable Large Hepatocellular Carcinoma: a Multicenter, Prospective, Nonrandomized Study
Conditions
Interventions
Drug-eluting bead transarterial chemoembolization (DEB-TACE)
Conventional transarterial chemoembolization (cTACE)
Locations
1
China
the Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Start Date
July 9, 2021
Primary Completion Date
July 8, 2024
Completion Date
July 8, 2024
Last Updated
September 15, 2022
NCT06707233
NCT05911633
NCT06187961
NCT06561399
NCT04224636
NCT06397222
Lead Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions